A comparative study of the efficacy of tacrolimus with infliximab in intractable ulcerative colitis
- Conditions
- lcerative colitis
- Registration Number
- JPRN-UMIN000010612
- Lead Sponsor
- Department of Internal Medicine, Division of Gastroenterology and Hepatology, Keio University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 130
Not provided
1. Patients with only proctitis. 2. Patients having contraindications to tacrolimus including current use of cyclosporine, bozentan, or potassium-sparing diuretics. 3. Patients having contraindications to infliximab including serious infection (sepsis), active tuberculosis infection, allergy to murine-derive proteins. 4. Patients who have been administered anti-TNF agents, tacrolimus, or cyclosporine. 5. Concomitant medication: 1) Changed the dose of oral 5-aminosalicylate (ASA) agents within 1 week. 2) Used topical 5-ASA agents or topical steroid agents within 1 week. 3) Underwent cytapheresis within 1 week. 4) Started an immunomodulator (azathioprine, mercaptopurine) within 12 weeks or changed the dose of the agent within 4 weeks. 5) Changed the dose of oral prednisolone within 1 week. 6) Changed the dose of intravenous prednisolone within 1 week. 6. Patients who have a serious infection or are suspected to have it. 7. Patients who have a serious cardiovascular disease. 8. Patients who have a serious renal disease (Serum Cr >= 2.0 mg/dl) 9. Patients who have a serious hepatic disease (Total bilirubin >= 3.0 mg/dl or AST or ALT >= 200 IU/ml) 10. Patients who are pregnant, possible to be pregnant, or want to be during the study period, or are breastfeeding. 11. Patients who have a neoplasm or had a neoplasm. 12. Patients who have a psychological disorder. 13. Patients who underwent resection of the colon (excluding appendectomy) 14. Patients who are judged to be exclusive by investigators for a certain reason.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical response rate at week 10 according to the DAI score.
- Secondary Outcome Measures
Name Time Method Clinical remission rate at week 10 DAI score at week 10 Endoscopic remission rate at week 10